Generic placeholder image

Reviews on Recent Clinical Trials


ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress

Author(s): Antiopi Voultsiadou and Vasiliki Sarli

Volume 6, Issue 3, 2011

Page: [271 - 277] Pages: 7

DOI: 10.2174/157488711796575522

Price: $65


Antimitotic chemotherapy remains the most effective approach to treat a variety of human neoplasms. Since the discovery of tubulin-targeting agents, vinca alkaloids and the taxanes including paclitaxel and docetaxel are used clinically to treat several solid tumors of the head and neck, breast, lung, ovary, and bladder. Despite the preclinical and clinical success of tubulin-targeting agents, the ability of tumors to develop an acquired resistance to drugs used for treatment and neurotoxicity severely limited their long-term effectiveness to cancer cure. Lately, advances in antimitotic treatments led to the identification of novel mitosis-specific agents that are expected to show higher selectivity and less cytotoxicity compared to known antimitotics. This review focuses on the progress of kinesin motor inhibitors that target proteins that function predominantly in mitosis.

Keywords: Antimitotics, Ispinesib, KSP kinesin, Mitotic kinesins, Neoplasms, Taxanes, Tubulin-targeting Agents, vinca alkaloids, paclitaxel

« Previous

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy